Mesenchymal stem cell therapy in necrotizing enterocolitis: a rat study

Area of Science:

• Regenerative Medicine
• Neonatal Research
• Gastroenterology

Background:

• Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease affecting premature infants.
• Current treatments for NEC have limited efficacy and significant side effects.
• Mesenchymal stem cells (MSCs) possess immunomodulatory and regenerative properties with therapeutic potential.

Purpose of the Study:

• To evaluate the therapeutic efficacy of exogenous human bone marrow-derived mesenchymal stem cells (hBM-MSCs) in a neonatal rat model of NEC.
• To assess the impact of hBM-MSC treatment on NEC-induced intestinal damage and clinical outcomes.

Main Methods:

• A rat model of NEC was established using enteral formula feeding, hypoxia-hyperoxia, and cold stress.
• Iron-labeled hBM-MSCs were administered intraperitoneally to NEC-induced pups.
• Histopathological and immunohistochemical analyses of the terminal ileum were performed on day four post-injection.

Main Results:

• Pups treated with hBM-MSCs exhibited significant weight gain and improved clinical sickness scores (p < 0.01).
• Histopathological evaluation revealed significantly reduced bowel damage severity in the hBM-MSC treated group compared to the NEC group (p = 0.012).
• A higher number of MSCs were observed to home to the bowel in the NEC + hBM-MSC group.

Conclusions:

• This study provides the first evidence of hBM-MSC effectiveness in a neonatal rat NEC model.
• hBM-MSC treatment significantly ameliorates NEC-induced intestinal damage.
• hBM-MSCs hold promise as a potential therapeutic strategy for necrotizing enterocolitis.